寿仙谷(603896) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥119,452,348.03, representing a decrease of 30.20% compared to the same period last year[2]. - Net profit attributable to shareholders was ¥17,797,076.96, down 63.77% year-on-year[2]. - Basic and diluted earnings per share were both ¥0.09, reflecting a decline of 64.00% from the same period last year[4]. - Total operating revenue for the first three quarters of 2024 was CNY 472,038,020.01, a decrease of 12.97% compared to CNY 542,632,310.78 in the same period of 2023[15]. - Net profit for the first three quarters of 2024 was CNY 118,670,397.66, a decline of 14.83% compared to CNY 139,360,766.88 in 2023[16]. - Total profit for the first three quarters of 2024 was CNY 118,570,291.55, down 15.09% from CNY 139,669,498.81 in the same period of 2023[16]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥142,988,211.23, a decrease of 26.61% compared to the previous year[4]. - Cash flow from operating activities generated CNY 142,988,211.23, a decrease of 26.54% compared to CNY 194,838,611.40 in the previous year[17]. - The net cash flow from investment activities was 219,995,039.05 CNY, a significant improvement compared to -273,533,327.34 CNY in the previous period[18]. - Cash inflow from financing activities totaled 393,983,609.10 CNY, down from 970,639,947.09 CNY in the previous period[18]. - The net cash flow from financing activities was -244,724,725.20 CNY, worsening from -97,016,009.24 CNY in the previous period[18]. - The total cash and cash equivalents at the end of the period amounted to 694,326,614.03 CNY, compared to 1,094,001,665.36 CNY at the end of the previous period[18]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,054,467,037.35, a decrease of 3.78% from the end of the previous year[4]. - The company's current assets totaled RMB 1,534,435,413.40, down from RMB 1,806,845,938.88, indicating a decrease of about 15.06%[12][13]. - Cash and cash equivalents decreased significantly from RMB 1,503,962,472.53 to RMB 861,802,079.80, representing a decline of approximately 42.7%[12][13]. - The company's total liabilities decreased from RMB 1,003,065,665.30 to RMB 822,582,802.54, a reduction of approximately 18.0%[14]. - The equity attributable to shareholders rose from RMB 2,171,288,696.67 to RMB 2,231,884,234.81, reflecting an increase of about 2.8%[14]. Inventory and Expenses - The company reported a significant increase in inventory by 37.62%, attributed to the rise in consumable biological assets[8]. - Research and development expenses for the first three quarters of 2024 were CNY 31,810,538.64, down 20.19% from CNY 39,846,073.99 in 2023[15]. - Sales expenses decreased to CNY 211,632,839.22, a reduction of 8.27% from CNY 230,668,022.08 year-on-year[15]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 21,737[9]. - The largest shareholder, Zhejiang Shouxian Valley Investment Management Co., Ltd., held 28.61% of the shares[9].